Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1985 May;19(5):701–704. doi: 10.1111/j.1365-2125.1985.tb02699.x

Enalapril (MK421) activation in man: importance of liver status.

I Larmour, B Jackson, R Cubela, C I Johnston
PMCID: PMC1463833  PMID: 2988590

Abstract

The in vitro conversion of enalapril (MK421) to enalaprilic acid (MK422) in human autopsy tissues was examined. MK422 was measured by radioimmunoassay. Human cadaver liver was the only tissue in which significant conversion was demonstrated. The esterase activity was stable after post mortem. Autopsy liver tissues from patients with elevated ante mortem liver function tests were found to have a reduced rate of deesterification.

Full text

PDF
701

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Biollaz J., Schelling J. L., Jacot Des Combes B., Brunner D. B., Desponds G., Brunner H. R., Ulm E. H., Hichens M., Gomez H. J. Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system. Br J Clin Pharmacol. 1982 Sep;14(3):363–368. doi: 10.1111/j.1365-2125.1982.tb01992.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. DiCarlo L., Chatterjee K., Parmley W. W., Swedberg K., Atherton B., Curran D., Cucci M. Enalapril: a new angiotensin-converting enzyme inhibitor in chronic heart failure: acute and chronic hemodynamic evaluations. J Am Coll Cardiol. 1983 Nov;2(5):865–871. doi: 10.1016/s0735-1097(83)80233-2. [DOI] [PubMed] [Google Scholar]
  3. Heel R. C., Brogden R. N., Speight T. M., Avery G. S. Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy. Drugs. 1980 Dec;20(6):409–452. doi: 10.2165/00003495-198020060-00001. [DOI] [PubMed] [Google Scholar]
  4. Jackson B., McGrath B. P., Johnston C. I. Correlation between angiotensin converting enzyme inhibition and the acute hypotensive response to MK 421 in essential hypertension. Clin Exp Pharmacol Physiol Suppl. 1982;7:99–104. [PubMed] [Google Scholar]
  5. Johnston C. I., McGrath B. P., Matthews P. G., Jackson B. Treatment of hypertension with angiotensin converting enzyme inhibitors. Clin Exp Pharmacol Physiol Suppl. 1982;7:135–144. [PubMed] [Google Scholar]
  6. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES